Read article in the New York Times (USA)
Many (possibly even most) doctors in positions of being able to influence prescribing practices are in the pockets of the drug companies. Sleaze is rife in the medical profession. - See http://aboutsalt.blogspot.com/2006/07/sleaze-in-medical-profession.html
I invite you to read this page, the author of which has a particular interest in the drug, Seroxat - http://fiddaman.blogspot.com/2007_04_05_archive.html - Here is an extract from the page:
"I've looked through the pdf file for THE COMMITTEE ON SAFETY OF MEDICINES ANNUAL REPORT FOR 2004 and will show you all those members who have ties with Glaxosmithkline.
Remember, The Committee on the Safety of Medicines (CSM) was 'apparently' an independent advisory committee that for 40 years advised the UK Licensing Authority on the quality, efficacy and safety of medicines - In other words they offered advice to the MHRA. It was replaced on 30 October 2005 by the Commission on Human Medicines which combines the functions of both the former committee and the Medicines Commission
I've just gone through the declared Personal Interests to highlight the members whom had ties with Glaxosmithkline.
PERSONAL INTERESTS
MEMBER
Professor A Blenkinsopp - GSK Specific – Fees
Professor H Dargie - GlaxoSmithKline Consultancy
Dr M Donaghy - GSK Shares
Dr J C Forfar - GSK Shares
Dr R Leonard - GSK Fees/ Publicity work
Prof D J Nutt - GSK Consultancy Psychotropics and 300 shares
Professor J F Smyth - GSK Consultancy
Professor Christopher Bucke - SKB Shares
Prof Nicholas Mitchison - GSK Shares
Dr Brian J Clark - GSK PHD student funding
Professor Robert Booy - GSK Consultancy
Professor S M Cobbe - GSK Research grant
Professor J E Compston - GSK Consultancy
Dr A Glasier - GSK Shares (£10,000)
Dr Andrew A Grace - GSK Consultancy
Dr P Hindmarsh - GSK Consultancy on growth, probably lapsed by now
Professor P D Home - GSK Consultancy
Dr R F A Logan - GSK Shares
Professor R MacSween - SmithKline Beecham Shares
Professor J O’D McGee - SmithKline Beecham Shares
No comments:
Post a Comment